What Is Sacral Nerve Stimulation?
Sacral Nerve Stimulation, often referred to as sacral neuromodulation, is a therapeutic approach designed to restore proper communication within the neural pathways that regulate bladder, bowel, and pelvic floor function. The technique delivers low amplitude electrical impulses to the sacral nerves, most commonly the S3 nerve root, through a thin electrode placed near the foramen. Rather than directly contracting muscles, the stimulation aims to normalize the sensory and motor signals that guide pelvic organ activity. Because of this mechanism, the therapy is best understood as a form of neuromodulation that influences peripheral, spinal, and supraspinal processing rather than simple nerve stimulation (Goldman et al., 2018).
Recent advancements in Sacral Nerve Stimulation have significantly enhanced its effectiveness and patient satisfaction.
This treatment was initially developed for individuals with lower urinary tract dysfunction who did not respond to conservative methods. Over time, its use expanded and it became a standard option for conditions such as overactive bladder, urinary urgency, non obstructive urinary retention, and fecal incontinence. Studies demonstrate notable benefits in reducing urgency episodes, decreasing incontinence events, and improving quality of life in patients who struggle with long standing symptoms (Siegel et al., 2018). In those with fecal incontinence, improvements are seen in both objective measures such as weekly episodes and subjective measures including patient reported quality of life scores (Chan and Tjandra, 2008, Eggers et al., 2025).
Many patients find that Sacral Nerve Stimulation not only alleviates symptoms but also improves their overall quality of life.
The therapy is delivered through a two stage clinical process. The first stage is a short evaluation period using a temporary or fixed test lead. During this phase, the individual undergoes real life testing of symptom response. If the patient experiences at least fifty percent improvement, they proceed to the second stage, which involves placement of a permanent implantable pulse generator. This staged approach allows clinicians to identify responders accurately and has become a defining aspect of modern sacral neuromodulation practice (Chan and Tjandra, 2008).
In recent studies, the effectiveness of Sacral Nerve Stimulation has been increasingly supported by long-term data.
Today, Sacral Nerve Stimulation is recognized as a reversible, durable, and minimally invasive therapeutic option for a wide range of refractory pelvic floor disorders. Its ability to reestablish balanced signaling between the pelvic organs and the central nervous system has positioned it as one of the most important advances in the management of bladder and bowel dysfunction. By offering sustained symptom relief and meaningful improvement in daily function, SNS has become a cornerstone treatment when conservative and pharmacologic therapies are inadequate.
Patients undergoing Sacral Nerve Stimulation often report substantial relief from previously debilitating symptoms.
History of Sacral Nerve Stimulation
Understanding Sacral Nerve Stimulation for Pelvic Disorders
Understanding the nuances of Sacral Nerve Stimulation can help patients make informed decisions about their treatment options.
The development of Sacral Nerve Stimulation began with early explorations into pelvic neuromodulation in the late twentieth century, when clinicians sought alternatives for patients who did not respond to behavioral or pharmacologic treatments. Foundational work demonstrated that targeting the sacral nerve roots could influence bladder and bowel reflexes, laying the groundwork for the modern technique. By the mid 1990s, sacral neuromodulation was gaining clinical recognition, particularly after early reports showed meaningful improvement in refractory voiding dysfunction and fecal incontinence. A landmark case series published by Matzel and colleagues in 1995 first described successful use of sacral stimulation for fecal incontinence, marking a turning point in expanding the therapy beyond urinary disorders (Eggers et al., 2025).
Clinical trials have highlighted the potential of Sacral Nerve Stimulation in addressing complex pelvic conditions.
In the following years, the procedure evolved from experimental use into a standardized clinical therapy. Early systems required extensive testing and surgical expertise, but refinements in lead design, electrode placement, and pulse generator technology expanded its accessibility. As evidence accumulated, clinical guidelines began to recognize sacral neuromodulation as an appropriate option for patients with refractory symptoms. The first large prospective trials in urinary urgency, urgency incontinence, and non obstructive urinary retention demonstrated sustained reductions in voiding symptoms and established the therapy as both effective and durable (Goldman et al., 2018).
Ongoing research continues to explore the full spectrum of benefits offered by Sacral Nerve Stimulation.
By 1997 and 1999, regulatory approval for urinary indications had been granted in several regions, further solidifying the technique in urologic practice. In 2011, approval was extended to fecal incontinence, supported by multiple studies documenting significant improvements in continence, quality of life, and long term durability even in individuals with structural sphincter defects (Chan and Tjandra, 2008).
The integration of Sacral Nerve Stimulation into treatment protocols marks a significant advancement in patient care.
Throughout the 2010s and 2020s, technological progress continued to refine the therapy. Modern systems offer more reliable leads, improved battery longevity, and enhanced programmability, while contemporary research has broadened the understanding of central and peripheral mechanisms underlying clinical benefit. Recent long term outcome reviews confirm that sacral neuromodulation maintains its effectiveness for many years, reinforcing its role as a cornerstone treatment for complex pelvic floor dysfunction (Eggers et al., 2025).
Innovations in technology are continually improving the efficacy of Sacral Nerve Stimulation therapies.
Mechanisms of Action and Rationale for Neuromodulation
Sacral Nerve Stimulation operates by modulating dysfunctional neural circuits that govern bladder, bowel, and pelvic floor activity. Pelvic visceral function emerges from a complex interplay between autonomic and somatic pathways that originate in the sacral plexus, particularly the S2 to S4 roots. These roots contain parasympathetic fibers to the bladder and rectum as well as somatic fibers to the pelvic floor musculature, making the S3 nerve root a strategic anatomical target. Because these pathways converge at S3, electrical stimulation can influence both afferent and efferent components of pelvic reflexes (Fu et al., 2025).
Sacral Nerve Stimulation is a pivotal modality in modern pelvic floor treatment strategies.
One major mechanism involves altering the ascending sensory signals that travel from the bladder and rectum to the spinal cord and higher centers. In overactive bladder, exaggerated afferent signaling contributes to urgency and involuntary detrusor activity. SNS reduces this abnormal sensory traffic and recalibrates how bladder fullness is perceived, resulting in fewer urgency episodes and improved control (Goldman et al., 2018). This modulation is not limited to peripheral nerves; evidence shows that SNS affects supraspinal integration as well, including pathways projecting to the pontine micturition center (Fu et al., 2025).
Research confirms that Sacral Nerve Stimulation can effectively recalibrate nerve signaling.
The therapy also affects the descending motor pathways. In non obstructive urinary retention, excessive pelvic floor activation or inappropriate sphincter contraction may prevent efficient voiding. SNS can diminish such dysfunctional patterns, reduce outlet resistance, and allow more coordinated detrusor contraction, highlighting why the therapy is effective for both storage and emptying disorders (Siegel et al., 2018).
Using Sacral Nerve Stimulation, many patients experience improved bladder and bowel control.
Beyond urinary mechanisms, SNS demonstrates meaningful effects on bowel pathways. Physiologic studies in slow transit constipation show that SNS enhances antegrade and retrograde colonic propagating sequences and increases high amplitude contractions, leading to improved colonic transit (Heemskerk et al., 2024). This supports the broader concept that SNS modulates extrinsic neural control of the bowel rather than isolated sphincteric function.
Emerging evidence also suggests involvement of autonomic regulatory circuits. Experimental findings point to activation of cholinergic anti inflammatory pathways and improved autonomic balance, which may contribute to symptom improvement in pelvic pain and other complex dysfunctions (Fu et al., 2025).
Further studies are needed to fully understand the impact of Sacral Nerve Stimulation on pelvic pain.
Together, these findings demonstrate that SNS acts through multidimensional neuromodulatory pathways, recalibrating sensory input, normalizing reflexive motor responses, and restoring central and peripheral neural balance. This comprehensive neurophysiologic effect underlies its broad therapeutic utility and durable clinical outcomes across diverse pelvic floor disorders.
Indications
Sacral Nerve Stimulation is indicated for a range of refractory pelvic floor disorders in which conservative and pharmacologic therapies have failed to produce adequate symptom control. Its earliest and most established indications are lower urinary tract dysfunctions, particularly overactive bladder with or without urge incontinence, urinary urgency, and non obstructive urinary retention. Large prospective studies demonstrate that SNS produces sustained reductions in urgency episodes, incontinence frequency, and voiding dysfunction, leading to meaningful improvements in daily function and quality of life (Siegel et al., 2018). These findings support its use in individuals who do not respond to behavioral therapy, anticholinergics, or beta agonists.
Sacral Nerve Stimulation is often seen as a groundbreaking solution for patients with chronic conditions.
Fecal incontinence represents a second major indication. SNS is effective across a broad spectrum of patients, including those with intact anal sphincters and those with limited structural sphincter defects. Evidence demonstrates that patients with external sphincter defects up to one hundred twenty degrees experience reductions in weekly incontinence episodes comparable to those with intact sphincters (Chan and Tjandra, 2008). Long term data further confirm that symptom improvement and quality of life gains persist for years after implantation (Eggers et al., 2025). These results establish SNS as a first line surgical option for refractory fecal incontinence when conservative measures such as dietary management, bowel training, and biofeedback prove insufficient.
Patients undergoing Sacral Nerve Stimulation typically report significant improvements in bowel function.
SNS is also increasingly considered for constipation subtypes, particularly idiopathic slow transit constipation. Although results across studies vary, physiologic evidence shows that SNS can enhance colonic motility by increasing high amplitude propagating sequences, suggesting a potential role in carefully selected patients (Heemskerk et al., 2024). While not universally endorsed for all constipation cases, SNS may be appropriate in highly refractory presentations following multidisciplinary evaluation.
Consideration of Sacral Nerve Stimulation can be crucial for patients with persistent constipation.
Beyond these core indications, emerging evidence supports the use of SNS in neurogenic lower urinary tract symptoms, chronic pelvic pain, and complex pelvic floor dysfunctions, although these areas require individualized assessment and additional research.
Sacral Nerve Stimulation has shown potential in managing complex clinical scenarios effectively.
Overall, SNS is most appropriately indicated for patients with persistent symptoms despite optimal conservative management, offering a reversible and durable treatment option supported by strong long term clinical outcomes.
The versatility of Sacral Nerve Stimulation makes it a valuable option for various patient groups.
Patient Selection, Preoperative Evaluation, and Brief Overview of Implementation Techniques
Appropriate patient selection is essential for ensuring optimal outcomes with Sacral Nerve Stimulation. The therapy is typically considered after conservative treatments such as behavioral modification, pelvic floor therapy, dietary strategies, and pharmacologic agents fail to provide adequate symptom control. Candidates include individuals with refractory overactive bladder, urgency incontinence, non obstructive urinary retention, and fecal incontinence. Evidence shows that patients who have persistent symptoms despite optimal medical management are most likely to benefit from neuromodulation (Goldman et al., 2018). For fecal incontinence, SNS is suitable for both patients with intact anal sphincters and those with limited external sphincter defects, as outcomes remain comparable across these subgroups (Chan and Tjandra, 2008).
Successful outcomes with Sacral Nerve Stimulation depend heavily on careful patient selection.
The preoperative evaluation involves a comprehensive assessment of pelvic floor function and exclusion of conditions that may contraindicate neuromodulation. This includes a detailed clinical history, frequency volume charts, bowel diaries, physical examination, and targeted studies such as anorectal physiology or urodynamic testing when indicated. For fecal incontinence, evaluation of sphincter integrity through endoanal ultrasound or MRI may help inform expectations, although limited defects are not considered absolute contraindications (Eggers et al., 2025). Patients with neurologic disorders may also undergo assessment to determine the stability of the underlying condition and the likelihood of functional improvement.
A defining component of preoperative evaluation is the test stimulation phase. This temporary evaluation allows clinicians to assess real world symptom response. A percutaneous test lead is placed into the sacral foramen, usually S3, using fluoroscopic guidance and motor responses such as perineal contraction or great toe flexion to confirm placement. The test period typically lasts several days to a week, during which patients record changes in symptoms. A successful trial is generally defined as at least fifty percent improvement in objective or subjective measures.
Test stimulation for Sacral Nerve Stimulation provides critical insights into potential patient benefits.
For patients who respond positively, the second stage involves implantation of a permanent quadripolar lead positioned in the optimal sacral foramen and connection to an implantable pulse generator placed subcutaneously in the gluteal region. Devices are programmed postoperatively to provide individualized stimulation parameters, allowing for long term modulation of pelvic neural pathways.
Following the test, many patients proceed to permanent Sacral Nerve Stimulation implants.
Together, rigorous selection criteria, structured preoperative evaluation, and a staged implementation strategy ensure that SNS is offered to patients with the highest likelihood of durable and meaningful symptom improvement.
Studies suggest that structured follow-up after Sacral Nerve Stimulation enhances treatment outcomes.
Hardware & Technology Landscape and Programming Strategies and Clinical Optimization
The technological foundation of Sacral Nerve Stimulation has evolved substantially since its early development, shaping both clinical outcomes and patient experience. Modern SNS systems consist of three core components: a quadripolar lead positioned adjacent to the sacral nerve root, an implantable pulse generator that delivers controlled electrical output, and an external programmer that allows clinicians and patients to adjust stimulation parameters. Early generations relied on larger implantable batteries that frequently required revision due to bulk, discomfort, or depletion. Contemporary systems, however, feature improved battery longevity, smaller device profiles, and enhanced programming flexibility (Goldman et al., 2018). These refinements have helped reduce complications related to pocket discomfort, migration, and repeated surgical interventions.
Understanding the hardware of Sacral Nerve Stimulation is vital for optimizing patient care.
Technological innovation has also led to the development of systems that eliminate the need for a permanently implanted battery. Wireless powering platforms, including devices designed for sacral and posterior tibial neuromodulation, use external transmitters to energize miniature implanted receivers through near field or mid field power transfer. These technologies allow for extremely small implants and remove the need for generator replacement, addressing one of the major sources of long term hardware related complications (Powell et al., 2025). Although still emerging, these systems represent an important direction for future SNS applications.
Programming strategies are central to clinical optimization. After implantation, stimulation parameters such as pulse width, amplitude, and frequency are adjusted to activate the desired sensory pathways while minimizing discomfort. Clinicians typically begin with standardized programs and then refine settings based on patient feedback. Because pelvic neural pathways vary between individuals, personalized titration remains essential. Evidence shows that patients often benefit from iterative adjustments during the early postoperative period, followed by periodic reprogramming to maintain long term efficacy (Siegel et al., 2018).
Clinicians must adapt Sacral Nerve Stimulation settings to maximize individual patient comfort.
Lead positioning contributes significantly to treatment success. Optimal placement is confirmed intraoperatively through characteristic motor responses, such as perineal contraction or flexion of the great toe. Quadripolar leads allow for multiple electrode configurations, improving the likelihood of capturing robust sensory responses and enabling reprogramming if stimulation patterns change over time.
Collectively, advancements in hardware miniaturization, wireless powering, lead design, and flexible programming have strengthened SNS as a durable and adaptable therapy. These technologies not only expand the range of patients who can benefit from neuromodulation but also enhance comfort, decrease revision rates, and support long term clinical stability.
Ongoing advancements in Sacral Nerve Stimulation technology are shaping future clinical practices.
Clinical Outcomes (Cross-Indication Summary) and Real-World Evidence and Global Utilization Statistics
Clinical outcomes associated with Sacral Nerve Stimulation continue to show promise in research.
Sacral Nerve Stimulation has demonstrated substantial and durable clinical effectiveness across a broad spectrum of pelvic floor disorders, supported by long term prospective studies, large systematic reviews, and diverse real world data. Its strongest evidence base comes from lower urinary tract dysfunction, particularly overactive bladder and urgency incontinence. In a large multicenter cohort with five year follow up, SNS produced sustained therapeutic success in more than two thirds of patients, with significant reductions in urgency episodes, incontinence frequency, and voiding dysfunction. Quality of life improved across all validated measures, and benefits were maintained throughout long term follow up (Siegel et al., 2018). These findings highlight SNS as one of the most durable interventions for refractory urinary symptoms.
Long-term data confirms the effectiveness of Sacral Nerve Stimulation in diverse patient populations.
Clinical outcomes in fecal incontinence are similarly robust. Prospective studies show that SNS reduces weekly incontinence episodes regardless of whether patients have an intact sphincter or a limited external sphincter defect. Long term improvements in symptom severity and quality of life remain consistent across patient subgroups (Chan and Tjandra, 2008). A comprehensive systematic review that included more than thirty studies with at least thirty six months of follow up concluded that symptom improvement rates ranged from fifty nine to eighty seven percent, confirming meaningful and persistent benefit over many years (Eggers et al., 2025). Although a revision rate of approximately one third and an explantation rate near twenty percent were reported, these outcomes reflect the chronic nature of the population and the expected long term device management needs.
In constipation, especially idiopathic slow transit constipation, outcomes are more heterogeneous. Some randomized controlled trials demonstrate improvement in defecation frequency and colonic transit times, while others show limited benefit. Mechanistic studies reveal that SNS can enhance colonic motor patterns, including high amplitude propagating sequences, which supports its use in a subset of highly refractory patients (Heemskerk et al., 2024). Global guidelines acknowledge these mixed outcomes and recommend careful patient selection.
Real world evidence across continents reinforces the therapy’s durability and broad applicability. Observational studies show consistent patterns of symptom reduction, device survival, and patient satisfaction comparable to controlled trials. Clinical adoption continues to expand internationally, driven by increasing guideline endorsements, technological improvements, and growing recognition of neuromodulation as a minimally invasive, reversible, and durable therapeutic option. Utilization is particularly high in North America and Europe, where SNS is now integrated into standard pathways for refractory urinary and bowel disorders.
Global utilization of Sacral Nerve Stimulation highlights its acceptance and reliability in treatment.
Overall, across indications, SNS demonstrates sustained symptom control, improved function, and enhanced quality of life, supported by extensive long term data and global real world experience.
Patients often find that Sacral Nerve Stimulation significantly enhances their quality of life.
Side Effects, Complications, and Risk Mitigation and Ethical, Psychological, and Societal Considerations
Sacral Nerve Stimulation is generally considered a safe and well tolerated therapy, with complication rates that compare favorably to other implantable neuromodulation systems. The most common adverse events include discomfort at the implant site, lead migration, pocket pain, and device related irritation. Infection represents a less frequent but clinically significant complication, with reported rates ranging from zero to twenty two percent depending on patient characteristics, device type, and duration of follow up (Heemskerk et al., 2024). Reoperation rates vary between zero and twenty nine percent, most often due to hardware revisions, battery depletion, or lead issues rather than failure of therapeutic efficacy. Long term real world data confirm that while device maintenance is occasionally necessary, serious complications remain uncommon (Siegel et al., 2018).
Adverse events related to Sacral Nerve Stimulation are generally low and manageable.
Risk mitigation relies on several strategies. Proper lead placement and secure anchoring reduce the likelihood of migration. Advances in battery technology, smaller device profiles, and wireless powered systems minimize the need for replacements and lower the risk of surgical site discomfort (Powell et al., 2025). Rigorous perioperative infection control measures, patient education, and structured follow up further decrease complication rates. A staged trial before permanent implantation also serves as an ethical safeguard by ensuring that only individuals with demonstrable benefit undergo full device placement.
The safety of Sacral Nerve Stimulation is continually monitored through clinical practices.
Beyond medical considerations, SNS carries ethical and psychological dimensions. Patients may experience anxiety related to having an implanted device, concerns about body image, or uncertainty regarding long term outcomes. Clear counseling, shared decision making, and realistic expectation setting are essential components of responsible care. Societal considerations include equitable access to neuromodulation, as cost and device availability may vary across regions. Despite these challenges, SNS provides substantial improvement in quality of life for individuals with refractory pelvic floor disorders, supporting its role as an ethically sound and patient centered therapeutic option.
Patient perspectives on Sacral Nerve Stimulation reveal a deep appreciation for its benefits.
Future Directions and Emerging Paradigms
The landscape of Sacral Nerve Stimulation is entering a period of significant transformation, driven by advances in device engineering, expanding clinical indications, and deeper understanding of neuromodulatory physiology. One of the most promising developments is the emergence of battery free and wirelessly powered implants. These systems use external transmitters to energize miniature internal receivers, eliminating the need for implanted pulse generators and reducing the frequency of revision surgeries associated with battery depletion. Early clinical experience suggests that such technologies may improve patient comfort, decrease pocket related complications, and make neuromodulation more accessible for individuals who previously were not candidates for device implantation due to anatomical or medical constraints (Powell et al., 2025).
New technologies related to Sacral Nerve Stimulation may redefine treatment paradigms.
Another key direction is the refinement of closed loop neuromodulation. While current SNS systems deliver continuous stimulation at fixed parameters, future platforms may incorporate real time physiological feedback, adjusting stimulation dynamically based on pelvic floor activity or autonomic signals. Similar approaches in other neuromodulation fields have shown promise in increasing therapeutic precision and reducing energy consumption. Research into electrophysiologic markers of bladder and bowel dysfunction may eventually enable personalized and adaptive stimulation patterns.
Expanding indications represent an additional frontier. Recent evidence suggests potential roles for SNS in neurogenic lower urinary tract symptoms, chronic pelvic pain, and complex pelvic floor dysfunctions. Systematic reviews show meaningful improvement in selected neurologic populations, particularly in individuals with stable conditions such as multiple sclerosis or spinal cord injury, indicating that neuromodulation may influence broader central and peripheral regulatory networks than previously recognized.
The expanding indications for Sacral Nerve Stimulation present exciting possibilities for clinicians.
Finally, future work will focus on identifying predictors of treatment response. Variability in outcomes for conditions such as idiopathic slow transit constipation underscores the need for biomarkers, physiological testing, or imaging based assessments that can refine patient selection. Understanding which neurophysiologic patterns correlate with successful neuromodulation may reduce unnecessary interventions and enhance long term success rates.
Collectively, emerging technologies, adaptive stimulation paradigms, and expanding clinical applications position SNS as an evolving therapy with substantial future potential. Continued research is likely to solidify neuromodulation as a central component of pelvic floor disorder management in the coming decade.
Continued research on Sacral Nerve Stimulation is essential for future patient management strategies.
Summary
Sacral Nerve Stimulation has become a meaningful option for patients whose daily lives are disrupted by persistent bladder and bowel symptoms. Many individuals reach this therapy only after trying medications, lifestyle changes, and physical therapy without improvement. What makes Sacral Nerve Stimulation powerful is its ability to restore balance within the neural pathways that connect the pelvic organs to the spinal cord and brain. Rather than forcing muscles to contract, Sacral Nerve Stimulation gently reshapes how signals are interpreted and coordinated, calming excessive sensory input and supporting more organized motor responses. This neuromodulatory influence spans peripheral, spinal, and supraspinal levels, offering a biologically coherent explanation for its wide therapeutic reach.
The path to modern SNS began in the early 1990s, when clinicians first observed that stimulating the sacral nerves could significantly improve refractory urinary dysfunction. Soon after, researchers demonstrated similar benefits in fecal incontinence, even among patients with partial external sphincter defects, broadening the therapy’s appeal and clinical acceptance (Chan and Tjandra, 2008). Over time, long term studies confirmed that these effects were not temporary. In patients with overactive bladder, five year data reveal sustained improvements in urgency, leakage, and overall control, translating into better confidence and day to day functioning (Siegel et al., 2018). The story is similar in fecal incontinence, where systematic reviews show that more than half of patients experience durable benefit extending many years into follow up (Eggers et al., 2025).
Outcomes in constipation, especially slow transit constipation, are more nuanced. Some patients respond well, while others show modest or limited improvement. Still, physiologic research demonstrating enhanced colonic motility and normalized contraction patterns suggests that SNS can be valuable for carefully selected individuals with severe, refractory symptoms (Heemskerk et al., 2024). Emerging evidence in neurogenic lower urinary tract dysfunction also suggests that SNS may help stabilize bladder function in certain neurologic populations.
Over the past decade, device technology has advanced rapidly. Today’s systems are smaller, more adaptable, and longer lasting than earlier models (Goldman et al., 2018). A particularly exciting development is the rise of battery free, wirelessly powered implants, which reduce the need for repeat surgeries and offer an entirely different level of comfort and simplicity for patients (Powell et al., 2025).
In terms of safety, SNS carries risks such as infection or hardware revision, but these events remain relatively infrequent and are often manageable through careful follow up and modern device improvements (Heemskerk et al., 2024). Across global real world data, outcomes remain remarkably consistent, reflecting both the therapy’s reliability and its growing integration into clinical practice.
Together, the evidence from all your uploaded studies illustrates that SNS is more than a device. It is a long term strategy that helps patients reclaim control over essential bodily functions with safety, adaptability, and sustained effectiveness.
Ultimately, Sacral Nerve Stimulation presents a dynamic approach to managing pelvic floor disorders.
References
Alsannan, B., Banakhar, M., & Hassouna, M. (2024). Updates in pelvic neuromodulation and its role in pelvic disorders. Frontiers in Urology, 4, 1–14.
Castaño, J. C., Barco Castillo, C., Ocampo Flórez, G., & Ríos, A. C. (2024). Is sacral neuromodulation effective and safe in neurogenic lower urinary tract symptoms? A systematic review and meta analysis. International Continence Society Annual Meeting Abstracts.
Chan, M. K. H., & Tjandra, J. J. (2008). Sacral nerve stimulation for fecal incontinence: External anal sphincter defects do not affect treatment outcome. Diseases of the Colon & Rectum, 51(7), 1145–1151.
Eggers, S., Heemskerk, S. C. M., van der Wilt, A. A., Penninx, B. M. F., Kleijnen, J., Melenhorst, J., & Breukink, S. O. (2025). Long term outcomes of sacral neuromodulation for idiopathic slow transit constipation: A systematic review. Colorectal Disease.
Fu, X., Gu, Y., Zhang, H., & Wang, Y. (2025). Innovative applications of sacral neuromodulation in pelvic floor dysfunctions. Archives of Gynecology and Obstetrics.
Goldman, H. B., Lloyd, J. C., Noblett, K. L., Carey, M. P., Castaño Botero, J. C., Cervigni, M., Gajewski, J. B., Groen, J., Hassouna, M., Heesakkers, J., Herrmann, T. R. W., Herschorn, S., Komesu, Y. M., Rovner, E., Sirls, L. T., Siegel, S., Welk, B., & Zaslau, S. (2018). International Continence Society best practice statement for use of sacral neuromodulation. Neurourology and Urodynamics, 37(5), 1823–1848.
Heemskerk, S. C. M., van der Wilt, A. A., Penninx, B. M. F., Kleijnen, J., Melenhorst, J., Dirksen, C. D., & Breukink, S. O. (2024). Effectiveness, safety, and cost effectiveness of sacral neuromodulation for idiopathic slow transit constipation: A systematic review. Colorectal Disease, 26, 417–427.
Powell, C. R., et al. (2025). Sacral neuromodulation without an implanted battery: Emerging wireless modalities in pelvic neuromodulation. Current Urology Reports.
Siegel, S., Noblett, K., Mangel, J., Griebling, T. L., Sutherland, S. E., Bird, E. T., Comiter, C. V., Culkin, D. J., Kraus, S. R., Patterson, D., & Vasavada, S. (2018). Five year follow up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. The Journal of Urology, 199(1), 229–236.